Citations (22)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Christina M Wyatt & Paul E Klotman. (2006) Antiretroviral therapy and the kidney: balancing benefit and risk in patients with HIV infection. Expert Opinion on Drug Safety 5:2, pages 275-287.
Read now
Read now
David Nolan, Peter Reiss & Simon Mallal. (2005) Adverse effects of antiretroviral therapy for HIV infection: a review of selected topics. Expert Opinion on Drug Safety 4:2, pages 201-218.
Read now
Read now
Articles from other publishers (20)
Antonio C. Seguro, Pedro H. França Gois & Daniele Canale. 2018. HIV/AIDS. HIV/AIDS
207
217
.
Corinne Isnard-Bagnis, Blandine Aloy, Gilbert Deray & Jérôme Tourret. (2016) Néphrotoxicité du ténofovir. Néphrologie & Thérapeutique 12:3, pages 179-189.
Crossref
Crossref
Jérôme Tourret, Gilbert Deray & Corinne Isnard-Bagnis. (2013) Tenofovir Effect on the Kidneys of HIV-Infected Patients. Journal of the American Society of Nephrology 24:10, pages 1519-1527.
Crossref
Crossref
Frédéric-Antoine Dauchy, Sylvie Lawson-Ayayi, Renaud de La Faille, Fabrice Bonnet, Claire Rigothier, Nadia Mehsen, Ghada Miremont-Salamé, Charles Cazanave, Carine Greib, Francois Dabis & Michel Dupon. (2011) Increased risk of abnormal proximal renal tubular function with HIV infection and antiretroviral therapy. Kidney International 80:3, pages 302-309.
Crossref
Crossref
James J Kohler, Seyed H Hosseini, Elgin Green, Allison Abuin, Tomika Ludaway, Rodney Russ, Robert Santoianni & William Lewis. (2011) Tenofovir renal proximal tubular toxicity is regulated By OAT1 and MRP4 transporters. Laboratory Investigation 91:6, pages 852-858.
Crossref
Crossref
Nathalie Saidenberg-Kermanac’h, Leila Souabni, Virginie Prendki, Dominique Prie & Marie-Christophe Boissier. (2011) Normal plasma FGF23 levels kinetic in tenofovir-related hypophosphatemic osteomalacia in an HIV-infected patient with von Recklinghausen disease. Joint Bone Spine 78:3, pages 306-308.
Crossref
Crossref
James J. Kohler & Seyed H. Hosseini. 2011. Laser Capture Microdissection. Laser Capture Microdissection
267
277
.
Hassane Izzedine, Marianne Harris & Mark A. Perazella. (2009) The nephrotoxic effects of HAART. Nature Reviews Nephrology 5:10, pages 563-573.
Crossref
Crossref
Pablo Labarga, Pablo Barreiro, Luz Martin-Carbonero, Sonia Rodriguez-Novoa, Carmen Solera, Jose Medrano, Pablo Rivas, Marta Albalater, Francisco Blanco, Victoria Moreno, Eugenia Vispo & Vincent Soriano. (2009) Kidney tubular abnormalities in the absence of impaired glomerular function in HIV patients treated with tenofovir. AIDS 23:6, pages 689-696.
Crossref
Crossref
Mateusz Winiarczyk, Anna Sikora, Tomasz Mikuta & Alicja Wiercińska-Drapato. (2009) Nephrotoxicity of Tenofovir true or myth?. HIV & AIDS Review 8:3, pages 17-20.
Crossref
Crossref
Alexandre B. Libório, Lúcia Andrade, Leonardo V.B. Pereira, Talita R.C. Sanches, Maria H. Shimizu & Antonio C. Seguro. (2008) Rosiglitazone reverses tenofovir-induced nephrotoxicity. Kidney International 74:7, pages 910-918.
Crossref
Crossref
Marie Essig, Xavier Duval, Firas Al Kaied, Laura Iordache, Anne Gervais, Pascale Longuet, Francoise Blanchet, Gilles Peytavin & Catherine Leport. (2007) Is Phosphatemia the Best Tool to Monitor Renal Tenofovir Toxicity?. JAIDS Journal of Acquired Immune Deficiency Syndromes 46:2, pages 256-258.
Crossref
Crossref
Heidi M Crane, Bryan Kestenbaum, Robert D Harrington & Mari M Kitahata. (2007) Amprenavir and didanosine are associated with declining kidney function among patients receiving tenofovir. AIDS 21:11, pages 1431-1439.
Crossref
Crossref
Francesc Vidal, Joan Carles Domingo, Jordi Guallar, Maria Saumoy, Begoña Cordobilla, Rainel Sánchez de la Rosa, Marta Giralt, Maria Luisa Álvarez, Miguel López-Dupla, Ferran Torres, Francesc Villarroya, Tomas Cihlar & Pere Domingo. (2006) In Vitro Cytotoxicity and Mitochondrial Toxicity of Tenofovir Alone and in Combination with Other Antiretrovirals in Human Renal Proximal Tubule Cells. Antimicrobial Agents and Chemotherapy 50:11, pages 3824-3832.
Crossref
Crossref
A Winston, J Amin, PWG Mallon, D Marriott, A Carr, DA Cooper & S Emery. (2006) Minor changes in calculated creatinine clearance and anion-gap are associated with tenofovir disoproxil fumarate-containing highly active antiretroviral therapy. HIV Medicine 7:2, pages 105-111.
Crossref
Crossref
Jamshid Amanzadeh & Robert F ReillyJrJr. (2006) Hypophosphatemia: an evidence-based approach to its clinical consequences and management. Nature Clinical Practice Nephrology 2:3, pages 136-148.
Crossref
Crossref
Stefan Mauss. (2006) Treatment of viral hepatitis in HIV–coinfected patients–adverse events and their management. Journal of Hepatology 44, pages S114-S118.
Crossref
Crossref
Svetlana Karie, Vincent Launay-Vacher, Hassane Izzedine & Gilbert Deray. (2005) Néphrotoxicité des médicaments : veille bibliographique janvier 2003–décembre 2004. Néphrologie & Thérapeutique 1:5, pages 285-295.
Crossref
Crossref
David Nolan & Simon Mallal. (2005) Antiretroviral-therapy-associated lipoatrophy: current status and future directions. Sexual Health 2:3, pages 153.
Crossref
Crossref
Joel Shuster. (2017) Tenofovir-Associated Renal Problems: Hyperphosphatemia from OTC Bowel Preparations: Beta-Blocker Induced Quadriparesis: Two Adverse Reactions in the Same (Unlucky) Patient: Warfarin-Associated Hemorrhage: Benzodiazepines and Hip Fractures. Hospital Pharmacy 39:10, pages 940-943.
Crossref
Crossref